Soleus Capital Management, L.P. C4 Therapeutics, Inc. Transaction History
Soleus Capital Management, L.P.
- $1.29 Billion
- Q2 2025
A detailed history of Soleus Capital Management, L.P. transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Soleus Capital Management, L.P. holds 6,978,942 shares of CCCC stock, worth $18.9 Million. This represents 0.77% of its overall portfolio holdings.
Number of Shares
6,978,942
Previous 6,978,942
-0.0%
Holding current value
$18.9 Million
Previous $11.2 Million
10.63%
% of portfolio
0.77%
Previous 0.92%
Shares
16 transactions
Others Institutions Holding CCCC
# of Institutions
105Shares Held
57.2MCall Options Held
15.2KPut Options Held
0-
Wasatch Advisors Inc Salt Lake City, UT7.42MShares$20.1 Million0.06% of portfolio
-
Lynx1 Capital Management LP San Juan, PR7.1MShares$19.2 Million3.01% of portfolio
-
Orbimed Advisors LLC San Diego, CA6.83MShares$18.5 Million0.35% of portfolio
-
Morgan Stanley New York, NY4.75MShares$12.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$12.3 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $133M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...